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Trichloroethylene (TCE), a common metal
degreasing solvent, is considered to be the
major component in more than half the U.S.
Environmental Protection Agency hazardous
waste sites (Fay and Mumtaz 1996). Although
rodent bioassay studies have established that
exposure to TCE is associated with develop-
ment of neoplasia in a variety of organ systems
(Davidson and Beliles 1991), epidemiologic
studies have not provided support for analo-
gous susceptibility of humans (Lewandowski
and Rhomber 2005; Wartenburg et al. 2000).
Efforts to redefine the risk of TCE-induced
carcinogenicity have been driven by the ability
of this solvent to induce hepatocellular carci-
noma in the B6C3F1 mouse strain (Herren-
Freund et al. 1987). It is now well accepted
that hepatocarcinogenicity is caused by a
metabolite, trichloroacetate (TCA), although a
contribution by its dichloroacetate (DCA) ana-
log cannot be discounted at this time (Bull
2000; Bull et al. 2002).
TCE is metabolized in the liver (Figure 1),
predominately by cytochrome P450 enzyme
CYP2E1 (Lipscomb et al. 1997; Nakajima
et al. 1992), to chloral hydrate (CH). In turn,
CH is metabolized by either of two pathways:
oxidation to TCA catalyzed by aldehyde
dehydrogenase (ALDH), or reduction to a
noncarcinogenic metabolite, trichloroethanol
(TCOH), mediated by alcohol dehydrogenase
(ADH). Although the conversion of CH to
TCOH is considered to be reversible, the
extent to which this back-reaction contributes
to TCA pools in vivo is unclear. In the main,
the distribution of CH into its carcinogenic
(TCA) and noncarcinogenic (TCOH) metabo-
lites appears to depend on the relative activity
of the two pathways.
Animals and humans appear to handle
TCE in regard to absorption, distribution,
metabolism, and elimination in a qualitatively
similar fashion. It is thus attractive to use
physiologically based pharmacokinetic
(PBPK) models for dose and species extrapola-
tion. Several models have been developed for
this purpose using kinetic parameters (e.g., Km
and Vmax) derived from both human and ani-
mal studies (Clewell and Andersen 2004;
Fisher 2000).
It is well known that both ADH and
ALDH are polymorphic in humans and that
the isoforms may differ markedly in their
steady-state kinetic constants (Li et al. 2001).
The human hepatic ADH concerned with the
metabolism of ethanol is designated as class I
and is encoded by three genes, ADH1, ADH2,
and ADH3, which code for peptides α, β, and
γ (Ehrig et al. 1990; Xu et al. 1988; Yin et al.
1984). Because the active enzyme is a dimer,
human hepatic ADH may occur as any of 21
possible forms depending on the individual’s
genotype. Among Caucasians, β1 predomi-
nates (80–95%) over β2 (4–20%). Asians show
a reverse pattern (β1 ~ 30% and β2 ~ 70%).
About 25% of African Americans express the
β3 form of ADH in their livers. Of importance
for the present study, the kinetic parameters
Vmax and Km toward ethanol vary considerably
among the isomeric forms, with a resultant
range of about a 50-fold difference in their
ﬁrst-order rate constants (Vmax/Km). At ethanol
blood levels associated with intoxication
(10–20 mM), the rate of elimination of
ethanol in the liver appears to be most closely
associated with the Vmax of the individual’s
ALDH isoform and with the rate of regenera-
tion of the essential cofactor NAD+ from its
reaction product, NADH. Regarding CH, the
situation is less clear. At the low levels of TCE
in drinking water, the steady-state production
of CH may be very low, with corresponding
low levels of CH in the liver. Theoretically,
the ﬁrst-order rate constant for CH metabo-
lism would be the prime determinant of
elimination by this pathway.
ALDH is also polymorphic (Ehrig et al.
1990). For acetaldehyde metabolism, ALDH1
(cytosolic) and ALDH2 (mitochondrial)
appear to be the most important, with the
mitochondrial form contributing most of the
clearance. An aberrant (inactive) form of
ALDH2 occurs in many individuals of Asian
descent and has been considered to be respon-
sible for their lesser ability to metabolize
acetaldehyde generated from ethanol by ADH.
ALDH is active as a tetramer, and the presence
of even one inactive monomer in the tetramer
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BACKGROUND: Trichloroethylene (TCE) is a suspected human carcinogen and a common ground-
water contaminant. Chloral hydrate (CH) is the major metabolite of TCE formed in the liver by
cytochrome P450 2E1. CH is metabolized to the hepatocarcinogen trichloroacetate (TCA) by alde-
hyde dehydrogenase (ALDH) and to the noncarcinogenic metabolite trichloroethanol (TCOH) by
alcohol dehydrogenase (ADH). ALDH and ADH are polymorphic in humans, and these polymor-
phisms are known to affect the elimination of ethanol. It is therefore possible that polymorphisms
in CH metabolism will yield subpopulations with greater than expected TCA formation with asso-
ciated enhanced risk of liver tumors after TCE exposure.
METHODS: The present studies were undertaken to determine the feasibility of using commercially
available, cryogenically preserved human hepatocytes to determine simultaneously the kinetics of
CH metabolism and ALDH/ADH genotype. Thirteen human hepatocyte samples were examined.
Linear reciprocal plots were obtained for 11 ADH and 12 ALDH determinations.
RESULTS: There was large interindividual variation in the Vmax values for both TCOH and TCA for-
mation. Within this limited sample size, no correlation with ADH/ALDH genotype was apparent.
Despite the large variation in Vmax values among individuals, disposition of CH into the two compet-
ing pathways was relatively constant.
CONCLUSIONS: These data support the use of cryopreserved human hepatocytes as an experimental
system to generate metabolic and genomic information for incorporation into TCE cancer risk
assessment models. The data are discussed with regard to cellular factors, other than genotype, that
may contribute to the observed variability in metabolism of CH in human liver. 
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[Online 30 May 2006]signiﬁcantly impairs acetaldehyde elimination
and results in a “ﬂushing” reaction and nausea
in these individuals after ethanol ingestion.
Collectively, consideration of the known
polymorphisms of ADH and ALDH in
humans raises the possibility of signiﬁcant vari-
ation in the contribution of the two pathways
(conversion to TCOH by ADH or to TCA by
ALDH) in the elimination of CH formed in
the liver from TCE ingested in drinking water.
Because hepatocarcinogenicity is considered to
be related to TCA levels in the liver, this varia-
tion could contribute signiﬁcantly to relative
susceptibility among exposed humans.
The question of relative distribution of CH
to TCOH and TCA was examined by
Lipscomb et al. (1996) using 700 × g super-
natant fractions of homogenized livers from
humans, mice, and rats. They reported that in
all three species, TCOH was the major
metabolite when concentrations of CH were
below 1 mM. However, these studies were per-
formed by incubating CH/liver homogenate
separately with either NAD+ (for TCA forma-
tion) or NADH (for TCOH formation) at
optimal concentrations (0.9 mM) of nucleo-
tide. As discussed below, these experimental
conditions may not reﬂect the environment of
the intact hepatocyte, so it is unclear whether
kinetic constants obtained in vitro are predictive
of the in vivo situation.
Cryopreserved human hepatocytes are now
readily available from commercial sources and
hence offer the possibility of rapid assessment of
a large number of individuals with varying
genotypes. The present studies were undertaken
to determine whether cryopreserved hepato-
cytes could be used to examine the distribution
of CH into its carcinogenic and noncarcino-
genic metabolites and, if so, whether the activi-
ties of each pathway could be correlated with
ADH and ALDH genotypes. The data indicate
that cryopreserved hepatocytes readily metabo-
lized CH and that the data were amenable to
Lineweaver-Burke kinetic analysis. Although the
individual samples showed major differences in
activity for both pathways, the ratio of oxida-
tion to reduction was relatively constant. In
view of the relatively small number of human
samples (i.e., 13) in these initial studies, no cor-
relation could be made between enzymatic
activities and ADH/ALDH genotype. We also
discuss the possibility that factor(s) other than
ADH/ALDH genotype may inﬂuence activity
at low substrate concentrations.
Materials and Methods
Chemicals and materials. Cryopreserved human
hepatocytes were purchased from InVitro
Technologies (Baltimore, MD) and ZenBio
(Research Triangle, NC). The cells were stored
in liquid N2 until use. InVitroGRO HI incuba-
tion medium and Torpedo antibiotic mix were
purchased from InVitro Technologies. CH,
TCA, DCA, TCOH, RNase A, and ethidium
bromide were obtained from Sigma Chemical
Co. (St. Louis, MO). The DNeasy tissue kit
was obtained from Qiagen Inc. (Valencia, CA).
Eppendorf hot master mix was obtained from
Fisher Scientiﬁc (Freehold, NJ). Bovine serum
albumin (BSA) was purchased from Promega
Scientific (Madison, WI). ALDH and ADH
primers and restriction enzymes were obtained
from Integrated DNA Technologies (Coralville,
IA). Ten percent TBE (Tris-borate-EDTA)
Novex gels and TBE-running buffer were pur-
chased from Invitrogen (Carlsbad, CA). All
other reagents were analytical grade and pur-
chased from commercial sources.
Metabolism studies. Just before use the
hepatocytes were thawed according to the sup-
pliers’ instructions and counted; cell viability
was determined by trypan-blue exclusion.
Hepatocytes were diluted to a concentration of
1 × 106 cells/mL with InVitro Technologies HI
incubation medium containing Torpedo
antibiotic mix and transferred to reaction vials
in 0.5-mL aliquots. CH (0.06–2.5 mM) was
added in a small volume of incubation medium
to each vial. The cells were incubated with CH
for 10 min at 37°C with gentle shaking. After
the incubation period, three 10-µL aliquots
were withdrawn from each vial and placed in a
20-mL gas chromatography (GC) vial contain-
ing 200 µL esterizer (H2O/H2SO4/methanol,
6:5:1) to enable volatilization of the acetates.
The esterized samples were analyzed by gas
chromatography (GC) with electron-capture
detection for the presence of CH metabolites.
The reproducibility of this experimental
method was assessed in liver homogenates
(700 × g supernatant) prepared from an
untreated male Sprague-Dawley rat (ﬁve sepa-
rate suspensions of the same liver) and
untreated male B6C3F1 mice (four suspensions
from four individual male mice of the same
age). Excision of livers from anesthetized ani-
mals was carried out in accordance with the
Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal
Resources 1996) guidelines as adopted by the
National Institutes of Health. Frozen (–80°C)
pieces of these livers were thawed and homoge-
nized in 4 vol of homogenization buffer
(250 mM sucrose, 25 mM KCl, 1 mM dithio-
threitol, 0.5 mM EDTA, 10 mM HEPES,
20% glycerol) and centrifuged at 700 × g for
10 min at 4°C. The supernatant was removed
and kept on ice until use. Protein content of
the supernatant was determined as described
previously (Smith et al. 1985). NAD+, NADP+
(0.9 mM), and various concentrations of CH
were added to 0.5 mL of the supernatant. The
reactions were carried out at 37°C for 10 min.
Aliquots of each reaction mixture (10 µL) were
prepared for GC analysis as described above for
human hepatocytes. In each case, the experi-
mental variability did not exceed 10%.
GC analysis of CH metabolites was per-
formed essentially as described previously
(Muralidhara and Bruckner 1999). Samples
were analyzed on a PerkinElmer Autosystem
XL gas chromatograph ﬁtted with a headspace
autosampler and an electron-capture detector
(PerkinElmer, Inc., Wellesley, MA). Metabo-
lites were resolved using a 10 inch × 1/8 inch
outer-diameter stainless-steel column packed
with 10% OV-17 on Supelcoport (Supelco,
Bellefonte, PA). The temperatures for analyses
were as follows: the column was run isothermal
at 150°C, injector at 200°C, transfer line at
120°C, and detector at 360°C. Nitrogen was
used as the carrier gas at 60 mL/min with a
headspace pressure of 20 psi. The samples were
heated at 110°C in the autosampler chamber
for 30 min before injection into the GC; run
time was 8 min. The metabolites were quanti-
fied against a standard curve using authentic
DCA, TCOH, and TCA (10–1,000 ng).
ADH and ALDH genotyping. Determina-
tion of ADH and ALDH genotype was per-
formed on the same cryopreserved hepatocytes
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Figure 1. Metabolism of TCE to CH and subsequent disposition into its carcinogenic (TCA) and noncarcinogenic
(TCOH) pathways.
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intermediatethat were used for the metabolism studies.
Detection of ADH2, ADH3, and ALDH2 was
performed using previously described methods
[Nakamura et al. 1993; human alcohol dehy-
drogenase (ADH; alcohol:NAD+ oxidoreduc-
tase, EC 1.1.1.1), UniGene accession no.
P07327 (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?CMD=search&DB=unigene);
human (mitochondrial) aldehyde dehydroge-
nase (ALDH2), EC 1.2.1.3, UniGene accession
no. P05091; and human (cytosolic) aldehyde
dehydrogenase (ALDH1), EC 1.2.1.3, UniGene
accession no. P00352]. DNA was isolated from
approximately 5 × 105 cells using a Qiagen
DNeasy Tissue Kit with the RNase A step.
Polymerase chain reaction (PCR) ampliﬁcation
of the ADH and ALDH alleles was performed
using the primers and restriction enzymes listed
in Table 1. Primers were constructed based
upon previously reported sequences (Burnell
et al. 1989; Ehrig et al. 1990; Mulligan et al.
2003; Osier et al. 1999; Yin et al. 1984). Each
reaction mixture contained 20 µL Eppendorf
hot master mix, 1 µL of 5 µM forward primer,
1 µL of 5 µM reverse primer, 17 µL sterile
water, and 10 µL isolated DNA template. PCR
was carried out using the following conditions:
4 min at 95°C, 1 min at 95°C, 1 min at 55°C,
1 min at 72°C, second and fourth steps cycled
34 times, 30 min at 72°C, and hold at 4°C.
The PCR products were isolated from the
whole DNA by restriction enzyme digest.
Brieﬂy, to the 20 µL PCR reaction mixture we
added 5.5 µL H2O (RNase, DNase free), 3 µL
buffer, 1 µL restriction enzyme, and 0.5 µL
BSA. The reaction was carried out at 37°C
for 2–3 hr. The digest product (10 µL) was
separated by gel electrophoresis using a 10%
TBE Novex gel and visualized with ethidium
bromide. The gel was run for 20 min at 200 V
to obtain optimal PCR fragment separation. A
100-bp DNA ladder was run concurrently with
the samples for determination of product
molecular weight. The gels were photographed
for analysis using Biorad Quantity One
ChemDoc software (BioRad, Hercules, CA).
Statistical analysis. Data were analyzed
using Stata software (version 8.2; StataCorp LP,
College Station, TX), and robust regressions
were performed to remove outliers. The “rreg”
command was used to ﬁt the regression model;
the ﬁnal kinetic values were determined using
this method. SAS software (version 9.0; SAS
Institute Inc., Cary, NC) was used to determine
the reproducibility of the assay procedure that
employed the mouse and rat liver homogenates.
Results
CH metabolism by liver homogenates: species
comparison. Appreciable species-related dif-
ferences have been reported for the kinetic
constants of CH metabolism into TCOH and
TCA by liver homogenates (Lipscomb et al.
1996). To validate our experimental assay pro-
cedure, we examined the capacity of rat and
mouse liver homogenates to metabolize CH to
TCOH and TCA. The kinetic constants (Km
and Vmax) obtained for the conversion of CH
to TCOH (Table 2) were in the 100- to
400-µM range and were similar to values
reported previously.
The Km values obtained for TCA formation
were in the 100- to 200-µM range and compa-
rable to those seen for TCOH formation by the
same liver fraction. Although these values are
notably lower than those observed by Lipscomb
et al. (1996), it is of interest that the calculated
ﬁrst-order rate constants (Vmax/Km) for TCA
formation showed the same species rank order:
mouse > human > rat.
CH metabolism in isolated human hepa-
tocytes. Because metabolism of CH to TCA
and TCOH by liver homogenates requires
addition of NAD+ and NADH, respectively,
the activity of each pathway must be examined
in separate incubations. To avoid the compli-
cation introduced by the different reaction
conditions in the assessment of the distribu-
tion of CH formed in the liver after ingestion
of TCE, we examined the suitability of iso-
lated human hepatocyte preparations for this
purpose. Cryogenically preserved human
hepatocytes (~ 10 × 106 cells/sample) were
obtained commercially, thawed, and equili-
brated in the recovery buffer as recommended
by the supplier. Cell viability was then deter-
mined, and the cells were resuspended to give
a final density of 1 × 106 viable cells/mL of
incubation mixture.
Preliminary studies established that the
metabolism of CH in the hepatocyte suspen-
sions was linear with time for 10 min at 37°C
over a concentration range of 0.05–2.0 mM.
The double-reciprocal plot of the simultaneous
metabolism of CH to TCOH and TCA by one
human hepatocyte sample (CHD) is illustrated
in Figure 2.
Table 3 lists the demographic and lifestyle
characteristics of the donors of the 13 human
hepatocyte samples supplied by the vendors.
Nonlinear kinetics was observed in the forma-
tion of TCOH in two individuals (HL7 and
HL8), and for TCA formation in one individ-
ual (HL6). The reason for nonlinear kinetics in
these samples is unknown, although this phe-
nomenon has been described previously using
ethanol as a substrate (Dalziel and Dickinson
1966). The apparent kinetic constants for the
other individual hepatocyte samples and their
genotypic forms of ADH and ALDH are
shown in Table 4. The means of these values
Human hepatocytes in TCE risk assessment
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Table 1. Primer sequences and restriction enzymes used in ALDH and ADH genotyping.
Isoform (primer ID) Primer sequence Restriction enzyme
ALDH2 (YC3) 5´-TTG GTG GCT AGA AGA TGT C-3´ MboII
ALDH2 (YC4) 5´-CCA CAC TCA CAG TTT TCT CTT-3´ MboII
ADH2 (A2F) 5´-ATT CTA AAT TGT TTA ATT CAA GAA G-3´ MsII
ADH2 (A2R) 5´-ACT AAC ACA GAA TTA CTG GAC-3´ MsII
ADH2 (424) 5´-TGG ACT CTC ACA ACA AGC ATG GT-3´ AluI
ADH2 (290) 5´-TTT CTT TGG AAA GCC CCC AT-3´ AluI
ADH2 (352) 5´-TCT TTC CTA TTG CAG TAG C-3´ AluI
ADH3 (321) 5´-GCT TTA AGA GTA AAT ATT CTG TCC CC-3´ SspI
ADH3 (351) 5´-AAT CTA CCT CTT TCC GAA GC-3´ SspI
Table 2. Kinetics of TCOH and TCA formation from CH in 700 × g supernatants obtained from present data
compared with data in the literature.
Present data Lipscomb et al. (1996) data
Vmax Km Vmax Km
TCOH
Rat 9.1 0.37 24.3 0.52
Mouse
High afﬁnity 8.9 0.11 6.3a 0.12
Low afﬁnity 6.1 0.51
Human ND ND 34.7 1.34
TCA
Rat 2.5 0.20 4.0 16.41
Mouse 8.9 0.10 10.6 3.50
Human 3.9 0.17 65.2 23.90
ND, not determined. Vmax is expressed as nmol/min/mg 700 × g supernatant protein. Km is expressed as mM CH. 
aInhibited above 0.57 mM CH.
Figure 2. Lineweaver-Burke plot of the raw data
points (n = 3) for TCOH and TCA formation in a sus-
pension of one human hepatocyte sample (CHD).
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TCA(Km of 0.06 ± 0.18 and 0.12 ± 0.03 mM, and
Vmax of 75.3 ± 38.4 and 53.9 ± 26.2
nmol/min/mg, respectively, for TCOH and
TCA formation) are generally similar to those
previously reported for the 700 × g fraction of
human liver homogenates (Lipscomb et al.
1996). Of note, however, is the wide variation
in the derived Km and Vmax values among indi-
viduals for both TCOH and TCA formation.
Because the two pathways may be regarded
as competing for CH, it was of interest to com-
pare the relative activity of the two pathways in
the various individuals. Figure 3 shows a plot
of the Vmax for TCOH formation against the
Vmax for TCA formation for each of the hepa-
tocyte preparations. The values appear to clus-
ter along the diagonal of the graph, indicating
that increase in one activity is matched by
increase in the other. This relationship suggests
that, although the activity of each pathway
varies signiﬁcantly among individuals, the dis-
position of CH into the two metabolites is
constant. This relationship was further exam-
ined by calculation of the ﬁrst-order rate con-
stants (Vmax/Km) for the two enzymatic
pathways. Figure 4 shows the plot of the ﬁrst-
order rate constants for TCOH versus TCA.
Although less striking than those for the Vmax
plots, there appears to be a similar tendency to
cluster along the diagonal, again indicating that
the disposition of CH into the two pathways
among the individual samples is relatively con-
stant regardless of the large variation in activity
of the two individual pathways.
Discussion
It is now well appreciated that humans vary
considerably in susceptibility to environmental
toxicants and that this variability is of major
concern in assessing the risk posed by hazardous
chemicals for human health (Aldridge et al.
2003). The factors determining variability
include genetics, age, sex and disease state, both
alone and in combination. The complexity of
the situation is further compounded by the
need to extrapolate from high-dose levels used
in rodent bioassays to chronic low-dose levels
typical of drinking water exposure in humans.
Currently, uncertainty factors may be used to
account for human variability, and “average”
kinetic values are used in PBPK models for
dose extrapolation. Clearly, our ability to
account for human variability in response to
hazardous chemicals would be greatly improved
if arbitrary uncertainty factors could be replaced
by quantitative measurement and the “average”
kinetic constants by values appropriate to the
various populations at risk (Gentry et al. 2002).
Obtaining kinetic data from prospective
clinical studies to encompass the range of
human genetic variability clearly presents
major difﬁculties. The growing availability of
cryogenically preserved human hepatocytes
could partially solve this dilemma in that it
may be practical to perform kinetic and genetic
analyses on a large number of donors in a rapid
and cost-effective manner. The present studies
were undertaken to determine the feasibility of
using cryopreserved cells as a sampling source
to probe the relationship between genotype
and metabolic disposition into toxic versus
nontoxic pathways of metabolism. CH was
chosen for this purpose because a) it is a
known intermediate in the pathway that gener-
ates a carcinogenic metabolite (TCA) from an
environmental contaminant (TCE); b) it is
cleared competitively by two pathways, one
leading to TCA and the other to the non-
carcinogenic metabolite TCOH; and c) the
enzymes concerned with its clearance (ALDH/
ADH) are polymorphic in humans. Because
the objective was to determine if the cells could
be used immediately after thawing, no recovery
or passage procedures were used beyond the
suppliers’ instructions.
Experimentally, 13 samples of cryopre-
served human hepatocytes were obtained com-
mercially, thawed and reconstituted as directed,
and incubated with various concentrations of
CH. Metabolite formation was quantitated and
used to generate the kinetic constants Km and
Vmax (Figure 2). These cells were also used to
determine ADH and ALDH genotypes.
As shown in Table 4, nine of the samples
had the ADH2β1β1 genotype for ADH, and
four were ADH2β1β2. Nine samples were
ADH3γ1γ1 and four were ADH3γ1γ2. In
regard to metabolism, two samples (HL7 and
HL8) yielded nonlinear kinetics for TCOH
formation and were excluded from calcula-
tion. The basis for the aberrant kinetic behav-
ior is unknown. The remaining values gave
mean Km and Vmax values of 0.06 ± 0.018
mM and 75.3 ± 38.4 nmol/min/106 cells,
Bronley-DeLancey et al.
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Figure 3. Plot of Vmax versus Vmax for ADH and
ALDH activities in human hepatocyte suspensions
given CH. Vmax values were determined from linear
regression analysis of the raw data points.
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Table 3. Donor characteristics of cryopreserved human hepatocytes.
Cellsa Donor age (years) Sex Race Tobacco use Alcohol use Substance abuse
AOK 47 M C Y N N
CEC 48 M C Y Y Y
DAD 62 M C Y Y N
IOE 79 M C Y Y N
KTG 59 M C Y Y N
ZAG 59 M C Y Y N
CHD 72 F AA N N N
EJR 56 F C N N N
HL10 42 M AA Y Y Y
HL6 48 F C N N N
HL7 55 F C N N N
HL8 56 M C Y Y N
HL12 0.03 F C N N N
Abbreviations: AA, African American; C, Caucasian; F, female; M, male; N, no; Y, yes. 
aViability of hepatocytes when thawed was 84.6 ± 2.6% (mean ± SE).
Table 4. Kinetics of TCOH and TCA formation in relation to ADH and ALDH genotypes.
TCOH TCA
Donor Km Vmax ALDH2 ALDH3 Km Vmax ALDH2
HL12 0.043 0.590 β1β1 γ2γ2 0.005 1.200 2*1
CHD 0.829 2.360 β1β1 γ1γ2 0.040 1.220 2*1
KTG 0.700 33.330 β1β1 γ1γ1 1.130 4.150 2*1
HL10 2.440 12.070 β1β1 γ1γ1 0.240 4.350 2*1
CEC 0.093 4.420 β1β1 γ1γ1 0.294 4.590 2*1
IOE 0.270 6.990 β1β1 γ1γ1 0.410 6.760 2*1
HL6 0.001 0.540 β1β1 γ1γ2 ND ND 2*1
HL7 ND ND β1β1 γ1γ1 0.013 0.140 2*1
AOK 0.160 3.340 β1β1 γ1γ1 1.270 16.940 Nonreacting
HL8 ND ND β1β2 γ1γ1 0.329 0.410 2*1
DAD 0.130 1.450 β1β2 γ1γ1 0.220 0.710 2*1
ZAG 0.022 2.220 β1β2 γ1γ1 0.142 2.280 2*1
EJR 0.027 222.220 β1β2 γ1γ1 0.009 158.730 Nonreacting
Mean ± SE 0.060 ± 0.018 75.30 ± 38.36 0.124 ± 0.031 53.91 ± 26.21
ND, not determined. Km is expressed as mM CH; Vmax is expressed as nmol/min/mg cell protein.Human hepatocytes in TCE risk assessment
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respectively. In view of the limited representa-
tion of β2 and γ2 forms of the isoforms within
the samples, no conclusions could be drawn as
to the inﬂuence of genotype on susceptibility
to TCE hepatocarcinogenicity.
A similar situation was seen with the
ALDH kinetic parameters. All but two of the
samples had the same genotype (ALDH2*1).
The two samples that were not ALDH2*1 were
termed “nonreacting”; that is, the phenotype
was not that of the inactive form associated
with acetaldehyde intolerance. An additional
sample showed nonlinear kinetics. Within 
the series, the mean values for Km and Vmax
were 0.12 ± 0.03 mM and 53.9 ± 26.2
nmol/min/106 cells, respectively.
The most striking aspect of these results is
the large variation among the individual sam-
ples regardless of genotype. For both ADH
and ALDH, the Vmax values showed more
than a 10-fold variation, raising the possibility
that the uncertainty factor of 10 commonly
used to assess human variability may be an
underestimation.
However, as illustrated in Figure 1, pro-
duction of TCA from CH depends on the
ratio of the activities of both ADH and ALDH
rather than on ALDH alone. Accordingly, the
Vmax values for each pathway were plotted
against each other for each individual sample
(Figure 3). Although there was a significant
difference in the activities of the pathways
among the samples, it is noteworthy that their
ratios fall reasonably close to the diagonal. Of
interest, the sample EJR, which was an outlier
for both pathways, also showed a ratio that
approximated unity. Although not as striking,
a similar relationship could be observed when
the ﬁrst-order rate constants (Vmax/Km) for the
two pathways were plotted against each other
(Figure 4). Collectively, these data suggest that
in spite of large differences in the activities of
the individual pathways, the distribution of
CH into its noncarcinogenic and carcinogenic
metabolites may be relatively constant.
The reason for the large variability in ADH
and ALDH activity among these samples is not
known. However, a plausible explanation may
lie in the steady-state kinetics of CH elimina-
tion. It has long been known that ADH-
catalyzed oxidation of ethanol/reduction of
acetaldehyde is an equilibrium reaction in
which the direction and rate depend on both
the concentration of substrate (alcohol or alde-
hyde) and the concentration and form of the
pyridine cofactor (i.e., NAD+ or NADH). The
reaction has been described in terms of eight
kinetic constants (Dalziel and Dickinson
1966). Although the reaction yields linear dou-
ble-reciprocal plots and is hence amenable to
Lineweaver-Burke analysis, the kinetic parame-
ters derived are simplifications of the overall
Theorell-Chance mechanism (Theorell and
Chance 1951). Special cases exist where the rec-
iprocal plots are not linear. Of importance for
the present studies, the reaction appears to be
ordered with addition of pyridine nucleotide
preceding ethanol and the release of NADH
being the rate-limiting step (Ehrig et al. 1990).
Thus, the availability and form of the cofactor
can explain differences in the Vmax of the reac-
tion. Differences in Km values are less well
understood but may reflect inclusion of a
catalytic constant (Kcat) of ethanol oxidation/
acetaldehyde reduction in experimentally
observed values.
For the present studies, a simpliﬁed schema
appears adequate to explain most of the
observed activities and the apparent constant
ratio between the two pathways. As shown in
Figure 5, reduction of CH by the NADH/
ADH complex yields TCOH with subsequent
release of NAD+. The NAD+ would then be
available to react with ALDH, and the complex
would oxidize CH to TCA with subsequent
release of NADH. Thus, the reduction and oxi-
dation of CH by ADH and ALDH would be
independent of the initial NAD+:NADH ratio.
This interdependence may normalize the ratio
of oxidation and reduction, thus yielding the
observed approximate linear correlation
between the two pathways. This proposed
mechanism implies that there is no kinetic bar-
rier for pyridine nucleotide exchange between
the two enzymatic pathways, suggesting that
both enzymes are located in the same cellular
compartment. This situation would be satisﬁed
if the ALDH used for CH oxidation was the
cytosolic isoform (ALDH1) rather than the
mitochondrial isoform (ALDH2), which is
believed to be more important for the elimina-
tion of acetaldehyde generated from ethanol.
Future studies are needed to probe the role of
cellular pyridine nucleotide levels in the appar-
ent Km and Vmax values and to distinguish the
contribution of the two ALDH isoforms to
CH oxidation by their sensitivity to disulﬁram
(Ehrig et al. 1990).
Previous studies on the relative disposition
of CH into its oxidative and reductive pathways
used liver homogenates (Lipscomb et al. 1996).
Each pathway was measured in separate incu-
bations with optimal pyridine nucleotide con-
centrations and a concentration range of CH
of up to 20 mM. These investigators con-
cluded that TCOH formation predominated at
submillimolar concentrations of CH. The
unequal disposition of CH with preponderance
of TCOH formation has also been observed in
experimental animals. Abbas et al. (1996)
administered CH to B6C3F1 mice at doses of
10–300 mg/kg and reported an approximate
3:1 ratio for the ﬁrst-order rate constants for
TCOH versus TCA formation. The present
studies relied on endogenous levels of NAD+
and NADH within the hepatocytes and used a
CH substrate concentration range of 0.060–2.0
mM. Additional studies are warranted to deter-
mine whether the approximate 1:1 ratio seen in
these studies reﬂects the low level of CH sub-
strate or a low level of pyridine nucleotide in
the cryopreserved hepatocytes. It is also possible
that hepatocellular pyridine nucleotide levels in
humans are under genetic control and that at
very low levels of CH generated from drinking
water levels of TCE, the genetically determined
concentration of pyridine nucleotides may be
more important than the ADH/ALDH geno-
types of the exposed individual.
Collectively, the present studies show that
cryogenically preserved hepatocytes can provide
a cost-effective approach to the simultaneous
determination of the kinetics of elimination of
Figure 5. Proposed interdependence of oxidation and reduction of CH by ADH and ALDH (see “Discussion”
for description).
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Figure 4. Plot of ﬁrst-order rate constants (Vmax/Km)
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10,000CH by ADH and ALDH and the determina-
tion of ADH and ALDH genotypes of individ-
ual donors. Both metabolism and genotyping
can be done on as few as 107 cells. Application
of this approach to a larger number of ethni-
cally diverse donor samples would allow for
deﬁnition of the relationship between genotype
and susceptibility to TCE-induced liver
tumors. However, the studies also raise a num-
ber of fundamental questions, such as which
genes are important at very low (i.e., drinking
water) levels of exposure to environmental
chemicals. Is it the isoform of the metabolizing
enzyme or of a “housekeeping” gene that sets
the physiologic homeostasis of the cell? Genes
that control nucleotide formation and removal
would fall into this category. It is also impor-
tant, however, to characterize the cryogenically
preserved cells in greater detail. Although the
recovered cells in this study all showed high
viability, and their metabolic activity is
expressed in terms of viable cell number, it is
possible that their physiologic state may vary in
ways that affect the kinetic interpretation of
the data for PBPK modeling and subsequent
risk assessment. Additional studies directed at
normalizing the cellular physiologic homeosta-
sis of individual donor samples before experi-
mentation would allow distinction between
genetically endowed differences and treatment/
handling effects.
The 11 individuals in the present study
who showed the 2*1 polymorphism for
ALDH2 had a Vmax variability for the pathway
generating TCA of between one and two orders
of magnitude (Table 4). When the two non-
2*1 genotypic individuals were included, the
range of Vmax values was increased by an addi-
tional order of magnitude. This observation
may have implications for quantitative risk esti-
mation for environmental exposures to TCE in
the general population. In risk assessment a
default value of 10 is used as an uncertainty fac-
tor for genetic variability in the population.
The results of this study indicate that if Vmax is
used as the appropriate correlate to risk, then a
10-fold uncertainty factor is an underestimate.
For TCE, however, what is relevant in risk
assessment is the amount of TCA, which
depends on the Vmax values for TCA metabo-
lism as well as the Vmax for the competitive
pathway to TCOH. Thus, Figure 3 is the rele-
vant comparison and the Vmax values for TCA
and TCOH are about equal, at least within an
order of magnitude for all the samples. At lower
exposures, a comparison of the rate constants
(Vmax/Km) for the two competing pathways
would be relevant. Figure 4 shows a good corre-
lation with the two rate constants being approxi-
mately within an order of magnitude of each
other. This suggests that a 10-fold uncertainty
factor for genetic susceptibility is reasonable for
TCA-driven TCE carcinogenesis. Further
research is warranted to quantify the genetic
variation in liver cancer risk following environ-
mental TCE exposures due to the polymorphic
genes involved in its metabolism.
REFERENCES
Abbas RR, Seckel CS, Kidney JK, Fisher JW. 1996.
Pharmacokinetic analysis of chloral hydrate and its metabo-
lism in B6C3F1 mice. Drug Metab Dispos 24:1340–1346.
Aldridge JE, Gibbons JA, Flaherty MM, Kreider ML, Romano JA,
Levin ED. 2003. Heterogeneity of toxicant response: sources
of human variability. Toxicol Sci 76:3–20.
Bull RJ. 2000. Mode of action of liver tumor induction by
trichloroethylene and its metabolites, trichloroacetate and
dichloroacetate. Environ Health Perspect 108:241–259.
Bull RJ, Orner GA, Cheng RS, Stillwell L, Stauber AJ, Sasser LB,
et al. 2002. Contribution of dichloroacetate and trichloroac-
etate to liver tumor induction in mice by trichloroethylene.
Toxicol Appl Pharmacol 182:55–65.
Burnell JC, Li TK, Bosron WF. 1989. Puriﬁcation and steady-state
kinetic characterization of human liver beta 3 beta 3 alcohol
dehydrogenase. Biochemistry 28:6810–6815.
Clewell HJ, Andersen ME. 2004. Applying mode-of-action and
pharmacokinetic considerations in contemporary cancer
risk assessments: an example with trichloroethylene. Crit
Rev Toxicol 34:385–445.
Dalziel K, Dickinson FM. 1966. The kinetics and mechanism of
liver alcohol dehydrogenase with primary and secondary
alcohols as substrates. Biochem J 100:34–46.
Davidson IW, Beliles RP. 1991. Consideration of the target organ
toxicity of trichloroethylene in terms of metabolite toxicity
and pharmacokinetics. Drug Metab Rev 23:493–599.
Ehrig T, Bosron WF, Li TK. 1990. Alcohol and aldehyde dehydro-
genase. Alcohol Alcohol 25:105–116.
Fay RM, Mumtaz MM. 1996. Development of a priority list of chem-
ical mixtures occurring at 1188 hazardous waste sites, using
the HazDat database. Food Chem Toxicol 34:1163–1165.
Fisher JW. 2000. Physiologically-based pharmacokinetic models
for trichloroethylene and its oxidative metabolites. Environ
Health Perspect 108:265–273.
Gentry PR, Hack CE, Haber L, Maier A, Clewell HJ. 2002. An
approach for the quantitative consideration of genetic poly-
morphism data in chemical risk assessment: examples with
warfarin and parathion. Toxicol Sci 70:120–139.
Herren-Freund SL, Periera MA, Khoury MD, Olson G. 1987. The
carcinogenicity of trichloroethylene and its metabolites,
trichloroacetic acid and dichloroacetic acid, in mouse liver.
Toxicol Appl Pharmacol 90:183–189.
Institute of Laboratory Animal Resources. 1996. Guide for the
Care and Use of Laboratory Animals. 7th ed. Washington,
DC:National Academy Press.
Lewandowski TA, Rhomber L. 2005. A proposed methodology for
selecting a trichloroethylene inhalation unit risk value for
use in risk assessment. Regul Toxicol Pharmacol 41:39–54.
Li TK, Yin SJ, Crabb DW, O’Connor S, Ramchandani VA. 2001.
Genetic and environmental inﬂuences on alcohol metabo-
lism in humans. Alcohol Clin Exp Res 25:136–144.
Lipscomb JC, Garrett CM, Snawder JE. 1997. Cytochrome P450-
dependent metabolism of trichloroethylene: interindividual
differences in humans. Toxicol Appl Pharmacol 142:311–318.
Lipscomb JC, Mahle D, Brashear WT, Garrett CM. 1996. A
species comparison of chloral hydrate metabolism in blood
and liver. Biochem Biophys Res Commun 14:340–350.
Mulligan CJ, Robin RW, Osier MV, Sambuughin N, Goldfarb LG,
Kittles RA, et al. 2003. Allelic variation at alcohol metabolism
genes (ADH1B, ADH1C, ALDH2) and alcohol dependence in
an American Indian population. Hum Genet 113:325–336.
Muralidhara S, Bruckner JV. 1999. Simple method for rapid meas-
urement of trichloroethylene and its major metabolites in
biological samples. J Chromatogr B 732:145–153.
Nakajima T, Wang RS, Elovaara E, Park SS, Gelboin HV, Vainio H.
1992. A comparative study on the contribution of cytochrome
P450 isozymes to metabolism of benzene, toluene and
trichloroethylene in rat liver. Biochem Pharmacol 43:251–257.
Nakamura K, Iwahashi K, Matsuo Y, Suwaki H, Ichikawa Y. 1993.
Improved methods for genotype determination at the ALDH2
locus using PCR by introducing the MBOII recognition site
or conducting secondary PCR. Biochem Mol Biol Int
31:439–445.
Osier M, Pakstis AJ, Kidd JR, Lee JF, Yin SJ, Ko HC, et al. 1999.
Linkage disequilibrium at the ADH2 and ADH3 loci and risk of
alcoholism. Am J Hum Genet 64:1147–1157.
Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH,
Provenzano MD, et al. 1985. Measurement of protein using
bicinchoninic acid [published erratum. Anal Biochem
163(1):279]. Anal Biochem 150:76–85.
Theorell H, Chance B. 1951. Studies on liver alcohol dehydroge-
nase. 2. The kinetics of the compound of horse liver alcohol
dehydrogenase and reduced diphosphopyridine nucleotide.
Acta Chem Scand 5:1127–1144.
Wartenburg D, Reyner D, Scott C. 2000. Trichloroethylene and
cancer: epidemiologic evidence. Environ Health Perspect
108:161–176.
Xu YL, Carr LG, Bosron WF, Li TK, Edenburg HJ. 1988. Genotyping
of human alcohol dehydrogenases at the ADH2 and ADH3
loci following DNA sequence amplification. Genomics
2:209–214.
Yin SJ, Bosron WF, Magnes LJ, Li TK. 1984. Human liver alcohol
dehydrogenase: puriﬁcation and kinetic characterization of
the beta 2 beta 2, beta 2 beta 1, alpha beta 2, and beta 2
gamma 1 “oriental” isoenzymes. Biochemistry 23:5847–5853.
Bronley-DeLancey et al.
1242 VOLUME 114 | NUMBER 8 | August 2006 • Environmental Health Perspectives